Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
NEW YORK, June 16, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT), a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is pleased to announce the appointment of Morten Albrechtsen, to its Board of Directors.
Morten Albrechtsen MD, BBA is a seasoned entrepreneur and investor with a strong medical, commercial and financial background. He has great depth within most therapeutic areas and with both drugs and devices. Mr. Albrechtsen’s development expertise includes all stages pre-clinical, clinical and post-market development, and most disciplines. He has international commercialization expertise and has helped with sales through partners, affiliates and direct to patients, hospitals and direct to end-users.
Morten Albrechtsen is an experienced business leader with a strong medical, commercial and financial background. After holding executive positions at several large pharmaceutical companies, including Boehringer Ingelheim and Nycomed (later acquired by Takeda Pharmaceutical), he founded ENKAM Pharmaceuticals in 2001. Since then, he has divided his time between consultancy work and executive roles, primarily at companies 2–4 years prior to cash-generating transactions. In addition to his role at Blake, Morten serves as co-founder and CEO at radiotherapy specialists Nanovi, part-time CEO at a number of pharma-related startups and executive chairman at the clinical CRO NORMA. Known as an expert deal-maker, Morten has extensive experience with turnarounds, spinoffs, business development, licensing and corporate deals, including M&A and financing.
“We are very happy to have Mr. Albrechtsen join our Board of Directors,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “Mr. Albrechtsen’s experience spans from pre-clinical and clinical development to regulatory approval and to post-approval commercialization, and comprises both biological products and small molecules and he is a strong asset to our team.” Morten will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™. Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact: Birger Jan Olsen, CEO Blake Insomnia Therapeutics Inc. 1(888) 612-2905 [email protected]
